Pfizer has launched its advanced 20-valent Pneumococcal Conjugate Vaccine (PCV20) for adults in India.

This next-generation vaccine significantly broadens protection against 20 serotypes of pneumococcal disease, a major step forward from previous vaccines.

Offered as a convenient single shot, PCV20 targets high-risk adults, including those with chronic health conditions, enhancing their defense.

This strategic market entry reinforces Pfizer's commitment to preventive healthcare and is poised to drive growth in the adult immunization segment.